… (n = 6707) or 20 mg/day tamoxifen (n = 6681) for 5 years. Gail's algorithm, based on a
multivariate logistic regression model using combinations of risk factors, was used to estimate the …

… -breaking model was used for diffusion; atoms with N near neighbours diffused with rate k N
… dissolution rate k E,N for a silver atom with N near neighbours was written as k E,N = ν E exp[…

PURPOSE To determine whether preoperative doxorubicin and cyclophosphamide (AC)
permits more lumpectomies to be performed and decreases the incidence of positive nodes in …

PURPOSE To determine, in women with primary operable breast cancer, if preoperative
doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan; AC) therapy yields a better outcome …

We conducted a randomized, double-blind, placebo-controlled trial of postoperative therapy
with tamoxifen (10 mg twice a day) in 2644 patients with breast cancer, histologically …

Background We have shown previously that lumpectomy with radiation therapy was more
effective than lumpectomy alone for the treatment of ductal carcinoma in situ (DCIS). We did a …

Results: The benefit of lumpectomy plus radiation was virtually unchanged between 5 and 8
years of follow-up and was due to a reduction in invasive and noninvasive ipsilateral breast …

… 5 years of tamoxifen (n = 322) or 5 years of placebo (n = 321). … were registered to receive
tamoxifen (n = 1211). Registered … years of tamoxifen (n = 261) or to 5 years of placebo (n = 249)…

Background and Methods Women with ductal carcinoma in situ have been treated both by
lumpectomy and by lumpectomy followed by radiation therapy, but the benefit of combined …

The National Surgical Adjuvant Breast and Bowel Project (NSABP) implemented protocol B-15
to compare 2 months of Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) and …